Insider · CIK 0001810995
Noreen Henig
Files at RNA (Avidity Biosciences, Inc.). First filing -, latest -.
Noreen Henig files SEC Form 4 as director at RNA (Avidity Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Noreen Henig has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Common Stock | -6,692 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,034 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,489 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,323 | - | - | 0 | Feb 27, 2026 |
| Feb 27, 2026 | RNA Avidity Biosciences, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,534 | - | - | 0 | Feb 27, 2026 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Common Stock | +6,692 | $0.00 | $0 | 6,692 | Jun 12, 2025 |
| Jun 10, 2025 | RNA Avidity Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +10,034 | $0.00 | $0 | 10,034 | Jun 12, 2025 |
Questions about Noreen Henig
Answered from the filings on this page, as of the latest one.
Is Noreen Henig buying or selling?
Noreen Henig has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Noreen Henig's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Noreen Henig has 0.
Where does Noreen Henig file Form 4?
Noreen Henig has filed Form 4 at RNA (Avidity Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.